Antibody-targeted chemotherapy with immunoconjugates of calicheamicin

Current Opinion in Pharmacology

Volumn 3, Issue 4, 2003, Pages 386-390

  Damle, Nitin K ^a   Frost, Philip ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ANTIBODY CONJUGATE; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CALICHEAMICIN DERIVATIVE; CD22 ANTIGEN; CD33 ANTIGEN; CMC 544; CYCLOSPORIN A; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DOUBLE STRANDED DNA; GEMTUZUMAB OZOGAMICIN; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY; PARACETAMOL; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BLOOD TOXICITY; CARDIOTOXICITY; CELL DEATH; CHILL; CLINICAL TRIAL; DISEASE MODEL; DNA STRAND BREAKAGE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FEVER; HUMAN; HYPOTENSION; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING; TUMOR CELL; TUMOR XENOGRAFT;

AMINOGLYCOSIDES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CLINICAL TRIALS; ENEDIYNES; HUMANS; IMMUNOCONJUGATES; LECTINS; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOMA, B-CELL;

EID: 0042303836     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(03)00083-3     Document Type: Review

References (37)

1. Trail P. Bianchi A. Monoclonal antibody drug conjugates in the treatment of cancer Curr Opin Immunol 11 1999 584-588
2. Dubowchik G. Walker M. Receptor-mediated and enzyme-dependent targeting of cytotoxic anti-cancer drugs Pharmacol Ther 83 1999 67-123
3. Lee M. Dunne T. Chang C. Siegal M. Morton G. Ellestad G. McGahren W. Borders D. Calicheamicins, a novel family of antibiotics. 4. Structural elucidations of calicheamicins J Am Chem Soc 114 1992 985-987
4. 1: an antitumor antibiotic that cleaves double-stranded DNA site specifically Science 240 1988 1198-1201
5. Thorson J. Sievers E. Ahlert J. Shepard E. Whitwam R. Onwueme K. Ruppen M. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research Curr Pharm Des 6 2000 1841-1879
6. Hinman L.M. Hamann P.R. Wallace R. Menendez A.T. Durr F.E. Upeslacis J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics Cancer Res 53 1993 3336-3342
7. Hinman L, Hamann P, Upeslacis J: Preparation of conjugates to monoclonal antibodies. In Endiyne Antibiotics as Antitumor Agents. Edited by Borders D, Doyle T. New York: Marcel Decker; 1995:87-106.
8. Hamann P. Hinman L. Beyer C. Kindh D. Upeslacis J. Flowers D. Bernstein I. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker Bioconjug Chem 13 2002 40-46
9. Hamann P. Hinman L. Hollander I. Beyer C. Lindh D. Holcomb R. Hallet W. Tsou H. Upeslacis J. Shochat D. et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia Bioconjug Chem 13 2002 47-58
10. DiJoseph J. Armellino D. Khandke K. Boghaert E. Dougher M. Kunz A. Hamann P. Moran J. Frost P. Damle N.CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of non-Hodgkin's lymphoma Eur J Cancer 38 2002 S150
11. DiJoseph J. Armellino D. Khandke K. Boghaert E. Dougher M. Sridharan L. Kunz A. Moran J. Hamann P. Frost P. Damle N. CMC-544, an anti-CD22 antibody-targeted calicheamicin therapeutic for the treatment of B lymphoid malignancies Blood 100 2002 160a
12. Boghaert E. Sridharan L. Armellino D. Khandke K. DiJoseph J. Kalyandrug L. Kunz A. Hamann P. Frost P. Damle N. A calicheamicin conjugate that targets LewisY selectively destroys LewisY-positive human carcinoma cells and xenografts Eur J Cancer 38Suppl 7 2002 S150-S151
13. Bross P. Beitz J. Chen G. Chen X. Duffy E. Kieffer L. Roy S. Sridhara R. Rahman A. Williams G. Pazdur R. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia Clin Cancer Res 7 2001 1490-1496
14. Berger M. Leopold L. Dowell J. Korth-Bradley J. Sherman M. Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse Invest New Drugs 20 2002 395-406
15. Andrews R. Singer J. Bernstein I. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties J Exp Med 169 1989 1721-1731
16. Sievers E. Applebaum F. Spielberger R. Forman S. Flowers D. Smith F. Shannon-Dorcy K. Berger M. Bernstein I. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 93 1999 3678-3684
17. Sievers E. Larson R. Stadmauer E. Estey E. Lowenberg B. Dombret H. Karanes C. Theobald M. Bennet J. Sherman M. et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 19 2001 3244-3254
18. Larson R. Boogaerts M. Estey E. Karanes C. Stadtmauer E. Sievers E. Mineur P. Bennett J. Berger M. Eten C. et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) Leukemia 16 2002 1627-1636
19. Sievers E. Larson R. Estey E. Lowenberg B. Leopold L. Berger M. Applebaum F. Mylotarg Study Group: final report of prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin followed by hematopoietic stem cell transplantation Blood 100 2002 89a
20. Linenberger M. Hong T. Flowers D. Sievers E. Gooley T. Bennett J. Berger M. Leopold L. Applebaum F. Bernstein I. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin Blood 98 2001 988-994
21. Naito K. Takeshita A. Shigeno K. Nakamura S. Fujisawa S. Shinjo K. Yoshida H. Ohnishi K. Mori M. Terakawa S. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemic cell lines but is inactive on P-glycoprotein-expressing sublines Leukemia 14 2000 1436-1443
22. Matsui H. Takeshita A. Naito K. Shinjo K. Shigeno K. Maekawa M. Yamakawa Y. Tanimoto M. Kobayashi M. Ohnishi K. Ohno R. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers Leukemia 16 2002 813-819
23. Walter R, Linenberger M, Hong T, Raden W, Bernstein I: Multidrug resistance protein (MRP) attenuates gemtuzumab ozogamicin (GO)-induced cytotoxicity in acute myeloid leukemia (AML). Blood 100:224b-225b.
24. Giles F. Kantarjian H. Kornblau S. Thomas D. Garcia-Manero G. Waddelow T. David C. Phan A. Colburn D. Rashid A. Estey E. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation Cancer 92 2001 406-413
25. Neumeister P. Eibl M. Zinke-Cerwenka W. Scarpatetti M. Sill H. Linkesch W. Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate Ann Hematol 80 2001 119-120
26. Rajvanshi P. Shulman H. Sievers E. McDonald G. Hepatic sinusoidal onstruction after gemtuzumab ozogamicin (Mylotarg) therapy Blood 99 2002 2310-2314
27. Chen A. Luger S. Sickles C. Mangan P. Porter D. Schuster S. Tsai D. Nasta S. Gewirtz A. Staudtmauer E. Gemtuzumab ozogamicin (Mylotarg™) therapy for relapsed AML after hematopoetic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease Bone Marrow Transplant 9 2002 23-28
28. Doll C. Yarbro J. Vascular toxicity associated with antineoplastic agents Sem Oncol 19 1992 580-596
29. Richardson P. Guinan E. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation Acta Haematol 106 2001 57-68
30. Erba H. Stadtmauer E. Larson R. Sievers E. Estey E. Löwenberg B. Leopold L. Berger M. Herbertson R. Appelbaum F.Results of a multivariate analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin Blood 100 2002 339a
31. Alvarado Y. Tsimberidou A. Kantarjian H. Cortes J. Garcia-Mancro G. Faderl S. Thomas D. Estey E. Giles F. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia Cancer Chemother Pharmacol 51 2003 87-90
32. Baccarani M. Durrant S. Linkesch W. Lechner K. Cooper M. Coutre S. Leopold L. White B. Richie M. Berger M. Preliminary report of a phase 2 study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine in patients with acute myeloid leukemia Blood 100 2002 341a
33. De Angelo D. Schiffer C. Amrein P. Fernandez H. Bradstock K. Tallman M. Foran J. Juliusson G. Liu D. Paul C. et al.Interim analysis of a phase 2 study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients <60 years old with untreated acute myeloid leukemia Blood 100 2002 198a-199a
34. Estey E. Giles F. Beran M. O'Brien S. Pierce S. Faderl S. Cortes J. Kantarjian H. Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia Blood 99 2002 4222-4224
35. Petti M. Pinazzi M.B. Diverio D. Romano A. Petrucci M. De Santis S. Meloni G. Tafuri A. Mandelli F. Lo Coco F. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676) Br J Haematol 115 2001 63-65
36. Li J.L. Shen G.L. Ghetie M.A. May R.D. Till M. Ghetie V. Uhr J.W. Janossy G. Thorpe P.E. Amlot P. Vitetta E.S. The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies Cell Immunol 118 1989 85-99
37. Hanna R. Ong G. Mattes M. Processing of antibodies bound to B-cell lymphomas and other hematological malignancies Cancer Res 56 1996 3062-3068